Tocilizumab in COVID-19: enthusiasm vs. evidence

Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeña-Huancas, Paola, León-Jiménez, Franco, Bryce-Alberti, Mayte, Portmann-Baracco, Arianna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614601/
https://www.ncbi.nlm.nih.gov/pubmed/34747742
http://dx.doi.org/10.4103/lungindia.lungindia_766_20
_version_ 1784603901280911360
author Zeña-Huancas, Paola
León-Jiménez, Franco
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna
author_facet Zeña-Huancas, Paola
León-Jiménez, Franco
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna
author_sort Zeña-Huancas, Paola
collection PubMed
description Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials.
format Online
Article
Text
id pubmed-8614601
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-86146012021-12-13 Tocilizumab in COVID-19: enthusiasm vs. evidence Zeña-Huancas, Paola León-Jiménez, Franco Bryce-Alberti, Mayte Portmann-Baracco, Arianna Lung India Case Report Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials. Wolters Kluwer - Medknow 2021 2021-10-26 /pmc/articles/PMC8614601/ /pubmed/34747742 http://dx.doi.org/10.4103/lungindia.lungindia_766_20 Text en Copyright: © 2021 Indian Chest Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Case Report
Zeña-Huancas, Paola
León-Jiménez, Franco
Bryce-Alberti, Mayte
Portmann-Baracco, Arianna
Tocilizumab in COVID-19: enthusiasm vs. evidence
title Tocilizumab in COVID-19: enthusiasm vs. evidence
title_full Tocilizumab in COVID-19: enthusiasm vs. evidence
title_fullStr Tocilizumab in COVID-19: enthusiasm vs. evidence
title_full_unstemmed Tocilizumab in COVID-19: enthusiasm vs. evidence
title_short Tocilizumab in COVID-19: enthusiasm vs. evidence
title_sort tocilizumab in covid-19: enthusiasm vs. evidence
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614601/
https://www.ncbi.nlm.nih.gov/pubmed/34747742
http://dx.doi.org/10.4103/lungindia.lungindia_766_20
work_keys_str_mv AT zenahuancaspaola tocilizumabincovid19enthusiasmvsevidence
AT leonjimenezfranco tocilizumabincovid19enthusiasmvsevidence
AT brycealbertimayte tocilizumabincovid19enthusiasmvsevidence
AT portmannbaraccoarianna tocilizumabincovid19enthusiasmvsevidence

Ejemplares similares